Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × Methyltestosterone × Clear all

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Phase 2 Recruiting

Prostatic Neoplasms